IKT at a glance
Inhibikase Therapeutics, Inc. (IKT, SEC CIK 1750149) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as October 21, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2024 (FY2024), Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and a net loss of $27.5 million. Diluted EPS was -$1.16.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Inhibikase Therapeutics, Inc. (IKT) shares worth $63.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2024
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 22 funds
- $63.0M · +0 vs prior quarter
- Latest 8-K
- Nov 10, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- China-related regulation: BIOSECURE Act restrictions could force transition from WuXi AppTec subsidiary STA, delaying IKT-001 supply
- Most material update: WuXi AppTec added to Section 1260H list in June 2026, with designation challenged and preliminarily enjoined August 7, 2026
- Compliance risk: proposed restrictions on China-based clinical data could limit trial-site use and increase development costs
- Operational risk: third-party manufacturing deviations or scale-up failures could delay clinical trials and product launches
- Supply-chain concentration: STA Pharmaceutical Hong Kong manufactures and supplies IKT-001 drug substance and drug product
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, no commercial product sales
- Net loss $20.5M vs $11.9M YoY, operating loss $22.2M vs $12.8M
- PAH R&D $12.5M vs $5.6M, strongest program, Parkinson’s R&D $0 vs $0.3M
- Cash, equivalents and marketable securities $193.3M at September 30, 2026
- Nine-month operating cash use $41.9M vs $20.3M, financing provided $53.3M
- Outlook: funding expected through topline Phase 3 readout, additional capital likely needed due to ongoing losses
AI summary of the IKT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for quarter ended September 30, 2026
- Corporate updates announced alongside quarterly results
Item EX-99.1: Item EX-99.1
- Phase 3 IMPROVE-PAH advancing: 28 countries approved and 79 of 180 planned sites activated
- Part A interim safety readout planned for first half of 2027, a near-term clinical catalyst
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Dennis Berman resigned as director and Compensation Committee Chair on October 19, 2026
- Scott Wasserman appointed independent Class III director through 2029 annual meeting
Item EX-99.1: Item EX-99.1
- Scott Wasserman appointed director effective October 19, 2026, replacing departing director Dennis Berman
- Experienced cardiovascular and metabolic drug developer, including leadership of Repatha, Evenity and Aimovig programs
Item 7.01: Regulation FD Disclosure
- Scott Wasserman appointed to Inhibikase Therapeutics’ board of directors
- Board appointment may influence governance, strategic oversight and shareholder confidence
Item EX-99.1: Item EX-99.1
- Phase 3 IMPROVE-PAH enrolling across 26 countries and 46 of 180 planned sites, validating late-stage execution
- IKT-001 targets PAH, a disease with approximately 30% five-year mortality and an estimated $8.3B antiproliferative market
Item 7.01: Regulation FD Disclosure
- Updated corporate presentation for investor and analyst meetings
- Presentation materials furnished as Exhibit 99.1
AI summaries of IKT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IKT
Don't miss the next IKT filing
- Alerts as it files. A push when IKT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IKT, by share count.
- Ask anything. An AI agent that reads every IKT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Wasserman Scott M. | A | Oct 19, 2026 | 310,000 | - |
| BERMAN DENNIS N | M | Jul 30, 2026 | 21,854 | $1.26 |
| BERMAN DENNIS N | M | Jul 30, 2026 | 21,854 | - |
| RA CAPITAL MANAGEMENT, L.P. | J | Jul 29, 2026 | 18,030,000 | - |
| RA CAPITAL MANAGEMENT, L.P. | J | Jul 29, 2026 | 18,030,000 | - |
| Aurentz Vincent | A | Jun 26, 2026 | 155,000 | - |
| BERMAN DENNIS N | A | Jun 26, 2026 | 155,000 | - |
| Kush Arvind | A | Jun 26, 2026 | 155,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | - |
| Operating Income | -$20.1M | -$28.6M | -$52.0M |
| Net Income | -$19.0M | -$27.5M | -$48.3M |
| Balance Sheet | |||
| Total Assets | $14.5M | $98.6M | $181.2M |
| Equity | - | $94.9M | $172.9M |
| ROE | - | -29.0% | -27.9% |
| Per Share | |||
| EPS | $-3.57 | $-1.16 | $-0.49 |
| Cash Flow | |||
| Operating CF | - | -$19.1M | -$27.8M |
| CapEx | $14K | $0 | $13K |
Source: XBRL data in Inhibikase Therapeutics, Inc. (IKT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate IKT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $63.0M |
| Q2 2026 | 22 | $58.7M |
| Q1 2026 | 23 | $43.9M |
| Q4 2025 | 19 | $37.0M |
| Q3 2025 | 17 | $17.0M |
| Q2 2025 | 15 | $19.4M |
| Q1 2025 | 9 | $13.5M |
| Q4 2024 | 6 | $16.8M |
- BlackRock+796.4K (+10%)
- State Street Corp+313.5K (+16%)
- Two Sigma Investments+202.2K (+25%)
- Bank of America Corp+189.2K (+175%)
- Morgan Stanley+179.7K (+158%)
- AQR Capital Management−151.5K (-32%)
- Blackstone Group−141.5K (-2%)
- Wells Fargo & Co−73.6K (-72%)
- Millennium Management−60.9K (-2%)
- Citigroup−23.1K (-41%)
- Dimensional Fund Advisors+103.1K
- FMR LLC (Fidelity)−103.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 133 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IKT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 10-Q | Nov 10, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 21, 2026 | - | - | - |
| 8-K | Oct 20, 2026 | - | Analysis | - |
| 8-K | Sep 8, 2026 | - | Analysis | - |
| 8-K | Aug 26, 2026 | - | Analysis | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 31, 2026 | - | - | - |
| 4 | Jul 31, 2026 | - | - | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| SC 13G | Jul 28, 2026 | - | - | |
| 8-K | Jul 23, 2026 | - | Analysis | - |
| SC 13G | Jul 17, 2026 | - | - | |
| 8-K | Jul 14, 2026 | - | Analysis | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 4 | Jun 30, 2026 | - | - | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 8-K | May 12, 2026 | - | Analysis | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 7, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
IKT SEC filings: frequently asked questions
Which institutions hold IKT stock?
As of September 30, 2026, the largest Inhibikase Therapeutics, Inc. (IKT) holders among the 13F filers tracked by SignalX were BlackRock ($17.6 million), Blackstone Group ($11.9 million), Vanguard Capital Management LLC ($10.4 million), Millennium Management ($8.2 million), State Street Corp ($4.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IKT's revenue in fiscal year 2024?
For the fiscal year ended December 31, 2024 (FY2024), Inhibikase Therapeutics, Inc. (IKT) reported revenue of $0 and a net loss of $27.5 million. Diluted EPS was -$1.16. The figures come from the XBRL data in the 10-K.
What did IKT report in its latest 8-K?
Inhibikase Therapeutics, Inc. (IKT) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.
What are the latest IKT SEC filings?
Inhibikase Therapeutics, Inc. (IKT) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on October 21, 2026.
What is IKT's SEC CIK number?
Inhibikase Therapeutics, Inc. (IKT)'s SEC Central Index Key (CIK) is 1750149. EDGAR lists every IKT filing under that number.
Ask anything about IKT
The research agent reads IKT's filings, financials, insider trades and 13F holders, then answers with sources.